These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29063853)

  • 1. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
    Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer.
    Xiang M; Nguyen PL
    Brachytherapy; 2015; 14(6):773-80. PubMed ID: 26489921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.
    King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF
    Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
    Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
    Muralidhar V; Chen MH; Reznor G; Moran BJ; Braccioforte MH; Beard CJ; Feng FY; Hoffman KE; Choueiri TK; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):828-35. PubMed ID: 26530751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
    Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
    Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
    Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
    Wattson DA; Chen MH; Moran BJ; Dosoretz DE; Braccioforte MH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e773-9. PubMed ID: 22300573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
    Rosenberg JE; Chen MH; Nguyen PL; Braccioforte MH; Moran BJ; D'Amico AV
    Clin Genitourin Cancer; 2012 Mar; 10(1):21-5. PubMed ID: 22130293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.
    Ashamalla H; Guirguis A; McCool K; McVorran S; Mattes M; Metzger D; Oromendia C; Ballman KV; Mokhtar B; Tchelebi M; Katsoulakis E; Rafla S
    Brachytherapy; 2017; 16(2):323-329. PubMed ID: 28139417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Adamovich E
    Brachytherapy; 2016; 15(1):79-84. PubMed ID: 26525214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy.
    Yang DD; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
    Urol Oncol; 2022 Jan; 40(1):6.e21-6.e27. PubMed ID: 34315661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
    Sebastian NT; McElroy JP; Martin DD; Sundi D; Diaz DA
    Urol Oncol; 2019 Nov; 37(11):813.e11-813.e19. PubMed ID: 31109836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.
    Muralidhar V; Catalano PJ; Reznor G; Mahal BA; Choueiri TK; Sweeney CJ; Martin NE; Beard CJ; Chen YW; Nezolosky MD; Hoffman KE; Feng FY; Trinh QD; Nguyen PL
    J Natl Compr Canc Netw; 2016 Apr; 14(4):421-8. PubMed ID: 27059190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.